All In Biotech

Drug Trial Radar · NCT06079190

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 367 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

367

Actual

Start

Oct 20, 2023

Primary completion

May 14, 2026

Study completion Aug 18, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Alector Inc.
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

Conditions

  • Alzheimer's Disease

Interventions

  • GSK4527226Drug

    GSK4527226 will be administered.

  • PlaceboOther

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76Time frame: Baseline, Week 52, 64 and 76

Locations

97 sites in 16 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Lake Mary, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Maitland, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Stuart, Florida

  • GSK Investigational Site

    The Villages, Florida

  • GSK Investigational Site

    The Villages, Florida

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Elk Grove Village, Illinois

  • GSK Investigational Site

    Chesterfield, Missouri

  • GSK Investigational Site

    Toms River, New Jersey

  • GSK Investigational Site

    Staten Island, New York

  • GSK Investigational Site

    Matthews, North Carolina

  • GSK Investigational Site

    North Canton, Ohio

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Fairfax, Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Melbourne, Australia

  • GSK Investigational Site

    Camperdown, New South Wales, Australia

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Kogarah, New South Wales, Australia

  • GSK Investigational Site

    Macquarie Park, New South Wales, Australia

  • GSK Investigational Site

    Gold Coast, Queensland, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Peterborough, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Greenfield Park, Quebec, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Kuopio, Finland

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.